SINTEF initiated research on continuous, cuffless blood pressure measurements with a focus on developing a wearable sensor that have higher resolution and is more comfortable than today's cuff-based blood pressure monitors.
SINTEF entered an agreement with Datek to further develop cuffless blood pressure technology into a commercial product.
The research project HyperSension received 16 million NOK in funding from the Norwegian Research Council. Here, Aidee Health and SINTEF collaborated with Oslo University Hospital, a global leader in hypertension research, and Sandefjord Helsepark, a group of General Practitioners, to develop a research-based, wearable, cuffless blood pressure device. This project was selected by the Research Council to spearhead their funding activities, and Torbjørn Røe-Isaksen, the Minister of Trade and Industry, visited us to gain insights into our research.
MD Sondre Heimark (Oslo University Hospital) started working on his PhD thesis, financed by the HyperSension project.
Datek created a spinout company named Datek Smart Health to bring the technology into the market.
Datek Smart Health changed its name to Aidee Health and the product defined as Aidee EmBody.
Aidee Health receives ISO-13485 certification. The certificate verifies that Aidee has a Quality Management System for Medical Devices complying with the ISO-13485:2016 standard.
Our consortium received 16MNOK funding from Norwegian Research Council for a new research project, Hypersension 2.0. MD Christine Hove from Oslo University Hospital started working on her PhD thesis, financed by the Hypersension 2.0 project.
Aidee Health receives the ISO-27001 certification and Normen/Norsk Helsenett approval. This demonstrates our strong expertise and commitment to information security and data protection. PhD candidate Sondre Heimark submits his PhD thesis.
This is the essence of the product. The goal is to reduce the mortality rate of undiagnosed and untreated high blood pressure.
The company has a stated policy that half of all employees in the company must be women. The company has both a female general manager and a female research manager.
Ambitions of global presence and to become a great workplace with employees in several countries.
The company is based on research and innovation, and has a policy that products and services will be created through research.
The plan is for production to be carried out in Europe as much as possible, and we have great focus on the external environment and rationalization of production and transport
The company is prepared for ISO-14001 certification (External Environmental Management System) and has processes and procedures for climate-friendly solutions, requirements for suppliers related to climate, etc.
Our product is the result of a unique collaboration between research institutions (Sintef and Ullevål), the primary health service (Ullevål and GPs at Sandefjord Helsepark) and the business community. This is a stated goal going forward, to further develop the products through collaboration and effective research